Full-Time

Principal Scientist/Sr. Principal Scientist

Computational Chemistry & Molecular Design

Antares Therapeutics

Antares Therapeutics

51-200 employees

Develops precision oncology therapeutics and pipelines

Compensation Overview

$185k - $240k/yr

Boston, MA, USA

Hybrid

In-office 2-3 days/week; Downtown Boston, Massachusetts.

Bachelor's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
Machine Learning
Medicinal Chemistry
Data Analysis

Get referred to Antares Therapeutics

See people who can refer or advise you

Requirements
  • PhD in computational chemistry, biophysics, theoretical chemistry, pharmaceutical sciences, cheminformatics, or a related quantitative field (or equivalent experience)
  • Principal Scientist: PhD with 10+ years (or bachelor's with 16+ years) of computational chemistry experience in a pharmaceutical and/or biotechnology setting. Senior Principal Scientist: PhD with 12+ years (or bachelor's with 18+ years), with a demonstrated track record of independent scientific leadership, cross-functional influence, and organizational impact.
  • Demonstrated, direct contributions to drug discovery programs through the application of computational chemistry — ideally including progression of compounds into or toward the clinic.
  • Deep, hands-on expertise across modern computational methods: structure- and ligand-based design, molecular dynamics, and free energy methods (e.g., FEP).
  • Proficiency with the Schrödinger suite and/or comparable platforms (e.g., MOE, OpenEye), and programming/scripting in Python and with coding assistants like Claude Code/Codex for cheminformatics and data analysis.
  • Strong understanding of medicinal chemistry, structural biology, and DMPK principles, and a proven ability to collaborate effectively in a fast-paced, matrixed, team-based environment.
  • Excellent written and verbal communication skills, with the ability to convey complex computational concepts to multidisciplinary audiences.
Responsibilities
  • Serve as the computational chemistry function lead on programs, providing integrated leadership across target validation, hit identification, hit-to-lead, and lead optimization for multiple small-molecule programs.
  • Apply structure-based and ligand-based design, molecular dynamics, and free energy perturbation (FEP) to prioritize compounds, evaluate druggability, and identify and exploit cryptic or novel binding pockets on challenging targets.
  • Integrate machine-learning, generative, and active-learning approaches into design-make-test-analyze cycles, and multiparameter optimization of potency, selectivity, and ADMET/physicochemical properties.
  • Partner closely with medicinal chemistry to translate computational hypotheses into synthesized, tested molecules, and to drive sound decision-making and smart risk-taking.
  • Lead computational infrastructure and platform development — identifying, evaluating, and deploying best-in-class tools, methods, and workflows — and contribute to major collaborations with external partners, in coordination with the Discovery Predictive Sciences team.
  • Analyze and integrate data across functions to independently identify, define, and address critical scientific issues and key scientific questions.
  • Communicate analyses, models, and recommendations clearly to project teams and leadership, influencing program strategy and portfolio decisions.
  • Represent computational chemistry in cross-functional program teams; help set design strategy and define the questions that computation should answer at each stage.
  • Mentor junior scientists and, at the Senior Principal level, provide broad scientific direction, establish best practices, and act as a recognized technical authority internally and in the external scientific community.
Desired Qualifications
  • Experience applying machine-learning and/or generative molecular design methods in a discovery setting is strongly preferred.
  • Experience in covalent drug discovery — including covalent docking, warhead selection and reactivity/selectivity assessment, and modeling of covalent kinetics (e.g., kinact/Ki) — is strongly preferred.
  • Proficiency with Python programming/scripting and use of coding assistants like Claude Code/Codex for cheminformatics and data analysis.
  • Strong communication and leadership demonstrated by cross-functional influence and organizational impact at senior levels.

Antares Therapeutics focuses on developing precision oncology medicines. It advances targeted cancer therapies by leveraging Scorpion Therapeutics’ discovery platform acquired by Lilly, using its validated pipeline and leadership with deep oncology experience to guide research and development. The company works by identifying cancer-specific targets and creating therapies that act on those targets, followed by clinical validation and eventual commercialization in advanced cancer indications. Its differentiation comes from access to Scorpion’s discovery capabilities, the support and resources of Lilly, and a leadership team with experience in oncology and life sciences, enabling a science-driven approach to push the boundaries of precision medicine. Antares aims to shape the future of precision oncology by delivering transformative treatments that can improve outcomes for cancer patients.

Company Size

51-200

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$282M

Headquarters

Boston, Massachusetts

Founded

2025

Get referred to Antares Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Novartis signed June 24, 2026, paying $105 million upfront and up to $1.8 billion.
  • Antares launched with $177 million on June 10, 2025, funding clinical entry in 2026.
  • Pierre Fabre and AstraZeneca collaborations broaden validation beyond Novartis and de-risk platform perception.

What critics are saying

  • Antares has no approved products, so the June 2026 Novartis options drive valuation.
  • Lilly kept STX-478, leaving Antares with less differentiated assets after March 2025.
  • If the 2026 lead trial disappoints, Novartis walks and Antares faces a financing crisis.

What makes Antares Therapeutics unique

  • Antares launched June 10, 2025 from Scorpion's pipeline, team, and discovery engine.
  • Adam Friedman and Scorpion veterans focus on historically undruggable oncology targets with small molecules.
  • Lilly's March 2025 Scorpion acquisition validated the platform before Antares inherited remaining assets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Performance Bonus

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

8%
Antares Therapeutics
Jul 9th, 2026
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets –

Informa TechTarget
Jun 25th, 2026
Novartis pays Antares $105M upfront in cancer drug collaboration worth up to $1.8B

Novartis will pay biotechnology startup Antares Therapeutics $105 million upfront in a multi-target research collaboration to discover new cancer medicines. Antares could receive up to $1.8 billion in additional milestone payments and low double-digit royalties on resulting products. Antares is a spinout of Scorpion Therapeutics that launched last year, developing experimental medicines left behind after Eli Lilly acquired one of Scorpion's drugs for up to $2.5 billion. The company also has research collaborations with Pierre Fabre Laboratories and AstraZeneca. The deal represents Novartis's latest effort to expand its oncology pipeline beyond radiopharmaceuticals, following recent acquisitions of MorphoSys and Mariana Oncology in 2024. Antares plans to advance its first precision oncology medicine into clinical trials later this year.

Yahoo Finance
Jun 24th, 2026
Novartis pays $1.9B to partner with Antares Therapeutics on undruggable cancer targets

Novartis has agreed to pay up to $1.9 billion to partner with Antares Therapeutics on discovering small molecule therapies for previously undruggable cancers. The deal includes $105 million upfront and up to $1.8 billion in milestone payments and royalties. Antares, which spun out from Scorpion Therapeutics in June 2025 with $177 million in Series A funding, will lead research using its proprietary drug discovery platform. The company applies compound libraries, mass spectrometry technology and pocket-finding approaches to tackle challenging oncology targets. Antares' lead precision oncology programme is expected to enter clinical trials in 2026. Novartis will have the option to license assets developed under the collaboration. Oncology generated $16.8 billion for Novartis in 2025, an 18% increase and its largest therapeutic segment.

Business Wire
Jun 11th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...

Pipeline Review
Jun 10th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

BOSTON, MA, USA I June 10, 2025 I Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing.